• Company
• Could Lilly Retatrutide be a game-changer for obesity drug?
• by Nho, Byung Chul Aug 14, 2023 05:21am

• Policy
• In order to activate new drugs & raw materials in Korea
• by Lee, Tak-Sun Aug 11, 2023 05:36am

• Company
• Imbruvica passed the drug reimbursement evaluation committee
• by Eo, Yun-Ho Aug 11, 2023 05:36am

• Policy
• GPP drug Spevigo is first approved in Korea
• by Lee, Hye-Kyung Aug 11, 2023 05:36am

• Policy
• PVG-004 succeeded in securing BA as the 1st generic K-CAB
• by Lee, Jeong-Hwan Aug 11, 2023 05:35am

• Policy
• 'Apply preferential pricing to non-inferior new drugs'
• by Lee, Tak-Sun Aug 11, 2023 05:35am

• Policy
• Health insurance finance approved by the government alone
• by Lee, Jeong-Hwan Aug 11, 2023 05:35am

• Company
• Will Darzalex be reimb as 2nd-line treatment for MM?
• by Eo, Yun-Ho Aug 11, 2023 05:35am

• Policy
• Out of stock of GLP-1 injections
• by Moon, sung-ho Aug 10, 2023 05:33am

• Opinion
• [Reporter's view] Prompt benefit registration
• by Eo, Yun-Ho Aug 10, 2023 05:33am